ArticleCureus2024
Epidemiology and Treatment Trends in the Management of Dupuytren's Disease From 2016 to 2022.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends in Treatment and Reimbursement of Dupuytren Disease.Journal of hand surgery global online · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The United States has been experiencing rapid demographic changes in recent years; therefore, it is crucial to understand how these changes affect the diagnosis and treatment of Dupuytren disease to provide high-quality patient care. This study examines the demographics of Dupuytren disease and its surgical management. Methods International Classification of Disease-10 (ICD-10) diagnostic codes were used to query the TriNetX database for all patients diagnosed with Dupuytren disease from 2016 to 2022. Current procedure terminology (CPT) codes were used to stratify the method of surgical interventions for Dupuytren disease and to form patient cohorts. Results The incidence of patients diagnosed with Dupuytren disease in the United States from 2016 to 2022 showed a steady annual increase in cases, peaking at 22,711 in 2022 compared to 11,271 in 2016. Most diagnoses occurred in patients aged 65-90 years, accounting for 72% of patients. Dupuytren disease was more prevalent in males (M/F ratio of 1.5/1) and White patients. Notable comorbidities included diabetes in 25% of patients, smoking history in 11% of patients, and hypothyroidism in 17% of patients. Patients with a smoking history had higher rates of surgical intervention, while those with hyperthyroidism had the highest rates of palmar fasciotomies. Males had higher rates of surgical intervention of all types compared to females. Overall, the highest surgical intervention rate was for partial fasciectomy, with single-digit release used in 9.9% of patients, and the lowest for palmar fasciotomy, used only in 1.4% of patients. Conclusion This study showed that the rates of Dupuytren disease are rapidly increasing in the United States. Additionally, there are significant differences in the diagnosis and treatment of Dupuytren disease based on patient demographics. Understanding these differences provides an opportunity to explore ways to tailor treatment and allocate resources to best meet patients' needs and improve the quality of care they receive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.